Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina PharmaCAI:ISPH +3.82%87 PB Ratio is 4.76 as of Aug. 06, 2026, which is 21% above its 10-year median of 3.95. GuruFocus rates CAI:ISPH with a GF Score™ of 87/100 and a GF Value™ of E£10.63 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 113 Medical Distribution companies, Ibnsina Pharma ranks worse than 88.5% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-06), Ibnsina Pharma's share price is E£13.60. Ibnsina Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was E£2.86. Hence, Ibnsina Pharma's PB Ratio of today is 4.76.
The historical rank and industry rank for Ibnsina Pharma's PB Ratio or its related term are showing as below:
CAI:ISPH'
s PB Ratio Range Over the Past 10 Years
Min: 0.93 Med: 3.95 Max: 19.33
Current: 4.75
During the past 10 years, Ibnsina Pharma's highest PB Ratio was 19.33. The lowest was 0.93. And the median was 3.95.
CAI:ISPH's PB Ratio is ranked worse than 88.5% of 113
companies
in the Medical Distribution industry
Industry Median: 1.03
vs CAI:ISPH: 4.75
During the past 12 months, Ibnsina Pharma's average Book Value Per Share Growth Rate was 32.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 30.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.20% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Ibnsina Pharma was 54.00% per year. The lowest was 4.60% per year. And the median was 15.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ibnsina Pharma PB Ratio Related Terms
Ibnsina Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ibnsina Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Ibnsina Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ibnsina Pharma (CAI:ISPH) has a PB Ratio of 4.76 as of Aug. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ibnsina Pharma and its competitors. This is 21% above median its historical median of 3.95. Over the past decade, Ibnsina Pharma's PB Ratio has ranged from 0.93 to 19.33. According to the industry distribution chart, Ibnsina Pharma ranks #100 out of 113 companies in the Medical Distribution industry, placing it in the top 88.5%.
Is Ibnsina Pharma's PB Ratio too high?
Ibnsina Pharma's current PB Ratio of 4.76 is 21% above median its 10-year median of 3.95. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 19.33. The Medical Distribution industry median PB Ratio is 1.03. Ibnsina Pharma's value of 4.76 is 362.1% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #100 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #100 out of 113 companies for PB Ratio. This places Ibnsina Pharma in the lower half of its industry. The industry median PB Ratio is 1.03. Ibnsina Pharma's value of 4.76 is 362.1% above this benchmark. Historically, Ibnsina Pharma's own PB Ratio has ranged from 0.93 to 19.33 over the past decade. While the company's 10-year median is 3.95 vs. the industry median of 1.03, Ibnsina Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current PB Ratio of 4.76 is 362.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current PB Ratio is 4.76, which is 21% above median its own 10-year median of 3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.63, compared to a current price of E£13.60 — trading 27.9% above its estimated fair value. The current PB Ratio is 4.76, which is 21% above median its 10-year median of 3.95 and 362.1% above the Medical Distribution industry median of 1.03. Ibnsina Pharma's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current PB Ratio is 4.76 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£13.60 is trading 27.9% above its estimated GF Value™ of E£10.63.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
PB Ratio: 4.76 (21% above median its 10-year median of 3.95)
GF Value™: E£10.63 vs. price of E£13.60 (27.9% above fair value)
Industry Position: 362.1% above the Medical Distribution median (#100 of 113)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
87GF Score
Get the complete analysis for CAI:ISPH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
